Stock Events

Stock Events

Scythian Biosciences 

0
14
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Feb 3Expected
Q4 2023
Q2 2026
Next
-0.07
0.27
0.6
0.93
Expected EPS
N/A
Actual EPS
N/A

Financials

1,521.03%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
278,163.96Revenue
4.23MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Microsoft
MSFT
Mkt Cap3.88T
Microsoft offers AI and analytics solutions that compete with Scryb's AI-driven analytics and cybersecurity products.
Alphabet
GOOGL
Mkt Cap3.44T
Google provides AI and machine learning technologies that rival Scryb's offerings in data analysis and predictive analytics.
International Business Machines
IBM
Mkt Cap243.66B
IBM's Watson and AI solutions offer competitive analytics and AI capabilities, challenging Scryb's market position.
Amazon
AMZN
Mkt Cap2.6T
Amazon Web Services (AWS) provides a wide range of AI and cloud computing services that compete with Scryb's analytics and AI solutions.
NVIDIA
NVDA
Mkt Cap4.94T
NVIDIA's AI and deep learning technologies power applications that compete with Scryb's AI-driven analytics.
Adobe
ADBE
Mkt Cap97.39B
Adobe's AI and analytics solutions in the Adobe Experience Platform present competition to Scryb's analytics offerings.
Salesforce
CRM
Mkt Cap188.61B
Salesforce offers AI-powered analytics and business intelligence solutions through its Einstein platform, competing with Scryb.
Oracle
ORCL
Mkt Cap396.13B
Oracle's AI and machine learning solutions for data analytics and business intelligence compete with Scryb's offerings.
Sap
SAP
Mkt Cap271.26B
SAP's AI and analytics solutions, including SAP HANA, offer competitive alternatives to Scryb's products in the enterprise market.

About

NorthPalm Capital Corp. engages in the development of cloud-based platform that focuses on cybersecurity business. It focuses on applied artificial intelligence, digital health, and biotech. The company was founded by James Samsoondar in 2005 and is headquartered in Toronto, Canada.
Show More
CEO
James van Staveren
Employees
8
Country
Canada
ISIN
CA7840531007
WKN
000A42B09

Listings

MU
DE
EIY.MU
STU
DE
EIY.STU
MU
DE
EIY0.MU
OTC Link
US
SCYRF

0 Comments

Share your thoughts

FAQs

What is Scythian Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Scythian Biosciences stocks are traded under the ticker 9SB.STU.
When is the next Scythian Biosciences earnings date?▼
Scythian Biosciences is going to release the next earnings report on February 3, 2027.
What is Scythian Biosciences revenue for the last year?▼
Scythian Biosciences revenue for the last year amounts to 278,163.96 EUR.
What is Scythian Biosciences net income for the last year?▼
9SB.STU net income for the last year is 4.23M EUR.
How many employees does Scythian Biosciences have?▼
As of November 7, 2026, the company has 8 employees.
In which sector is Scythian Biosciences located?▼
Scythian Biosciences operates in the Technology sector.
When did Scythian Biosciences complete a stock split?▼
The last stock split for Scythian Biosciences was on April 12, 2018 with a ratio of 4:1.
Where is Scythian Biosciences headquartered?▼
Scythian Biosciences is headquartered in Toronto, Canada.